X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5010) 5010
Book Review (1335) 1335
Publication (369) 369
Book Chapter (95) 95
Conference Proceeding (34) 34
Dissertation (9) 9
Reference (3) 3
Book / eBook (2) 2
Magazine Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3611) 3611
humans (3015) 3015
glucagon-like peptide-1 (1810) 1810
endocrinology & metabolism (1793) 1793
male (1613) 1613
type 2 diabetes (1486) 1486
diabetes mellitus, type 2 - drug therapy (1430) 1430
animals (1424) 1424
incretin (1369) 1369
glucose (1269) 1269
diabetes (1266) 1266
female (1146) 1146
insulin (1074) 1074
glp-1 (944) 944
hypoglycemic agents - therapeutic use (935) 935
incretins (934) 934
glucagon (844) 844
middle aged (831) 831
blood glucose - metabolism (789) 789
adult (755) 755
insulin - metabolism (642) 642
incretins - therapeutic use (608) 608
glycemic control (586) 586
obesity (582) 582
dextrose (572) 572
insulin secretion (570) 570
glucagon-like peptide 1 (565) 565
peptides (541) 541
insulin - blood (534) 534
mice (534) 534
diabetes mellitus, type 2 - blood (527) 527
liraglutide (520) 520
secretion (514) 514
pharmacology & pharmacy (509) 509
gastric-inhibitory polypeptide (492) 492
aged (489) 489
diabetes mellitus (482) 482
dipeptidyl-peptidase iv inhibitors - therapeutic use (481) 481
beta-cell function (480) 480
type-2 diabetes-mellitus (475) 475
diabetes mellitus, type 2 - metabolism (469) 469
glucagon-like peptide 1 - metabolism (465) 465
exenatide (459) 459
incretins - metabolism (455) 455
treatment outcome (449) 449
abridged index medicus (446) 446
rats (437) 437
analysis (429) 429
insulin resistance (424) 424
hypoglycemic agents - adverse effects (423) 423
incretin hormones (419) 419
blood glucose - drug effects (401) 401
internal medicine (389) 389
sitagliptin (388) 388
research (380) 380
glucagon-like peptide-1 receptor (378) 378
metformin (371) 371
hypoglycemic agents - pharmacology (358) 358
insulin-secretion (356) 356
care and treatment (355) 355
gip (355) 355
double-blind (352) 352
physiological aspects (352) 352
physiology (348) 348
hypoglycemic agents - administration & dosage (345) 345
medicine & public health (345) 345
glucagon-like peptide 1 - analogs & derivatives (343) 343
glucose metabolism (338) 338
type 2 diabetes mellitus (335) 335
glucagon-like peptide 1 - blood (332) 332
endocrine system (331) 331
hypoglycemic agents (329) 329
risk factors (326) 326
diabetes therapy (325) 325
hyperglycemia (323) 323
digestive, oral, and skin physiology (321) 321
dipeptidyl peptidase-4 inhibitor (320) 320
health aspects (316) 316
glucagon-like peptide 1 - therapeutic use (314) 314
medicine, general & internal (304) 304
incretin-based therapies (299) 299
glucose tolerance test (292) 292
drug therapy (291) 291
dependent insulinotropic polypeptide (290) 290
hormones, hormone substitutes, and hormone antagonists (289) 289
diabetes mellitus, type 2 - physiopathology (281) 281
hormones (279) 279
diabetes mellitus, type 2 - complications (271) 271
glucose - metabolism (270) 270
mellitus (269) 269
metabolism (251) 251
drug therapy, combination (247) 247
biochemistry & molecular biology (238) 238
incretins - pharmacology (233) 233
insulin-secreting cells - metabolism (233) 233
blood glucose - analysis (231) 231
review (229) 229
bariatric surgery (224) 224
glucagon-like peptide 1 - pharmacology (224) 224
diabetes-mellitus (222) 222
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4659) 4659
German (89) 89
French (64) 64
Spanish (56) 56
Japanese (52) 52
Czech (43) 43
Korean (28) 28
Hungarian (27) 27
Russian (21) 21
Italian (17) 17
Polish (11) 11
Chinese (5) 5
Portuguese (5) 5
Norwegian (4) 4
Danish (3) 3
Croatian (2) 2
Slovak (2) 2
Swedish (2) 2
Turkish (2) 2
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science Translational Medicine, ISSN 1946-6234, 10/2013, Volume 5, Issue 209, pp. 209ra151 - 209ra151
We report the discovery and translational therapeutic efficacy of a peptide with potent, balanced co-agonism at both of the receptors for the incretin hormones... 
MEDICINE, RESEARCH & EXPERIMENTAL | BODY-WEIGHT | GLYCEMIC CONTROL | HIGH-FAT DIET | GLUCOSE-INTOLERANCE | ENTEROINSULAR AXIS | PANCREATIC BETA-CELLS | DEPENDENT INSULINOTROPIC POLYPEPTIDE | GASTRIC-INHIBITORY POLYPEPTIDE | LIPOPROTEIN-LIPASE | PEPTIDE YY3-36 | CELL BIOLOGY | Acylation - drug effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Rodentia - metabolism | Weight Loss - drug effects | Hyperglycemia - drug therapy | Young Adult | Incretins - pharmacology | Adult | Female | Gastric Inhibitory Polypeptide - pharmacology | Receptors, Glucagon - agonists | Glucose Tolerance Test | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Rats | Receptors, Glucagon - metabolism | Treatment Outcome | Haplorhini - metabolism | Gastric Inhibitory Polypeptide - administration & dosage | Peptides - pharmacology | Insulin - metabolism | Animals | Glucagon-Like Peptide-1 Receptor | Adolescent | Aged | Mice | Venoms - pharmacology | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Receptors, Gastrointestinal Hormone | Incretins - administration & dosage | Liraglutide | Index Medicus | Medicin och hälsovetenskap | Medicinsk bioteknologi (inriktn. mot cellbiologi (inkl. stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) | Medicinsk bioteknologi
Journal Article
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 05/2010, Volume 26, Issue 4, pp. 287 - 296
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2016, Volume 18, Issue 5, pp. 491 - 499
Aims: Liraglutide 3.0 mg, an acylated GLP-1 analogue approved for weight management, lowers body weight through decreased energy intake. We conducted... 
body weight | pharmacokinetic | glucagon‐like peptide‐1 | incretin | DIABETIC-PATIENTS | ENERGY | glucagon-like peptide-1 | ENDOCRINOLOGY & METABOLISM | RANDOMIZED-TRIAL | OPEN-LABEL | APPETITE | Overweight - complications | Appetite Depressants - adverse effects | Obesity - drug therapy | Overweight - drug therapy | Humans | Middle Aged | Incretins - pharmacokinetics | Male | Weight Loss - drug effects | Appetite Depressants - therapeutic use | Obesity - blood | Prediabetic State - therapy | Diet, Reducing | Dose-Response Relationship, Drug | Glucagon-Like Peptide-1 Receptor - metabolism | Exercise | Liraglutide - pharmacokinetics | Diabetes Mellitus, Type 2 - therapy | Appetite Depressants - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Obesity - complications | Prediabetic State - complications | Sex Characteristics | Combined Modality Therapy - adverse effects | Overweight - therapy | Overweight - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Obesity - therapy | Incretins - therapeutic use | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Appetite Depressants - pharmacokinetics | Cohort Studies | Index Medicus | Original
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2034 - 2038
This study aimed to quantify the effect of the immediate release (IR) of exenatide, a short‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist (GLP‐1RA),... 
pharmacodynamics | 1 analogue | antidiabetic drug | GLP | dose–response relationship | incretin therapy | exenatide | GLP-1 analogue | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | dose-response relationship | Incretins - blood | Humans | Intestinal Absorption - drug effects | Glucagon-Like Peptide 1 - blood | Incretins - pharmacokinetics | Diabetes Mellitus, Type 2 - metabolism | Dietary Carbohydrates - metabolism | Systems Biology | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Hypoglycemic Agents - blood | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Postprandial Period | Exenatide - pharmacokinetics | Hypoglycemic Agents - therapeutic use | Digestion - drug effects | Hyperglycemia - prevention & control | Exenatide - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Blood Glucose - analysis | Drug Administration Schedule | Diabetes Mellitus, Type 2 - blood | Gastric Emptying - drug effects | Models, Biological | Drug Liberation | Exenatide - administration & dosage | Exenatide - blood | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Pharmacology | Hypoglycemic agents | Glucose | Glucagon | Dextrose | Gastric emptying | Glutamic acid receptors | Food intake | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 642 - 649
Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin. Methods In... 
metformin | GLP | receptor | type 2 diabetes | pharmacodynamics | Type 2 diabetes | Pharmacodynamics | GLP-1 | Metformin | Receptor | FASTING PLASMA-GLUCOSE | GLYCEMIC CONTROL | SAFETY | EXENATIDE | OPEN-LABEL | PEPTIDE-1 ANALOG | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | DOUBLE-BLIND | GLP-1 RECEPTOR AGONIST | PLACEBO-CONTROLLED TRIAL | Glycated Hemoglobin A - analysis | Metformin - therapeutic use | C-Peptide - blood | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Glucagon - blood | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Hyperinsulinism - prevention & control | Glucagon-Like Peptide 1 - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Care and treatment | Glucagon | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus | Original
Journal Article
Archives of Oral Biology, ISSN 0003-9969, 06/2019, Volume 102, pp. 238 - 243
Objective: To investigate the effects of sitagliptin, a dipeptidyl peptidase 4 inhibitor used to treat type II diabetes, on bone tissue and on implant... 
Incretins | Dipeptidyl peptidase 4 | Implants
Journal Article
Hormone and Metabolic Research, ISSN 0018-5043, 01/2015, Volume 47, Issue 1, pp. 84 - 87
Abstract The role of incretins in glucose homeostasis is well known. Yet, in recent years, the sustained weight loss and rapid glycemic control following... 
Mini Review | incretins | anti-incretin theory | pancreatic islets | metabolic surgery
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10019, pp. 679 - 690
Journal Article
The Journal of Nutritional Biochemistry, ISSN 0955-2863, 12/2016, Volume 38, pp. 154 - 161
Blackcurrants are rich in polyphenolic glycosides called , which may inhibit postprandial glycemia. The aim was to determine the dose-dependent effects of... 
Incretins | Berries | Postprandial glycemia | Polyphenols | Anthocyanins | Randomized controlled trial | Insulin | DIETARY POLYPHENOLS | HEALTHY-SUBJECTS | BIOCHEMISTRY & MOLECULAR BIOLOGY | RANDOMIZED-TRIAL | ACARBOSE | WOMEN | NUTRITION & DIETETICS | HYPERGLYCEMIA | ARTERIAL STIFFNESS | COTRANSPORTER | INTESTINAL ALPHA-GLUCOSIDASE | Incretins - blood | Humans | Middle Aged | Male | Anthocyanins - administration & dosage | Plant Extracts - administration & dosage | Hypoglycemic Agents - administration & dosage | Postprandial Period | Ribes - chemistry | Adult | Anthocyanins - therapeutic use | Female | Beverages | Meals | Hyperinsulinism - blood | Diet, Carbohydrate-Restricted | Hyperinsulinism - metabolism | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Incretins - antagonists & inhibitors | Blood Glucose - analysis | Double-Blind Method | Hyperinsulinism - prevention & control | Fruit - chemistry | Functional Food | Cross-Over Studies | Hyperglycemia - metabolism | Hyperglycemia - blood | Incretins - secretion | Diet, Carbohydrate Loading - adverse effects | Plant Extracts - therapeutic use | Anthocyanin | Postmenopausal women | Blood sugar | Fruit drinks | Fatty acids | Index Medicus | Tmax, Time of maximum concentration | L-BE, Low dose of blackcurrant extract | TAG, Triacylglycerol | GLP-1, Glucagon-like peptide-1 | DVP-SI, Digital volume pulse stiffness index | GIP, Glucose-dependent insulinotropic polypeptide | Cmax, Maximum concentration | H-BE, High dose of blackcurrant extract | NEFA, Non-esterified fatty acids | AOB, Area over baseline | M-BE, Medium dose off blackcurrant extract | CON, Control treatment | DVP-RI, Digital volume pulse reflection index
Journal Article